Navigation Links
BGI and START initiate collaboration to advance unique San Antonio 1000 Cancer Genome Project
Date:9/12/2013

most of which are local providers at community-based facilities where 90 percent of cancer care and where clinical studies occur. These hospitals are enrolling cancer patients into the research project, and collecting the tissue samples to be sequenced and analyzed. By working through this community network, referral bias (influence of disparate data source) will be avoided since the patient population will be typical of the representative cancer patient in the community, as opposed to patients in tertiary cancer centers. This increases the ability to generate large enough data sets for analysis through predicative algorithms that could ultimately explain underlying biological causes of cancer.

In contrast to past research, where sample preservation was formaldehyde based for 30 years, hematology and oncology researchers involved in SA1kCGP have agreed to change the paradigm for genomic oncology by using fresh tissue for this analysis. The logistics of obtaining fresh tissue is a major hurdle to large scale genomic research in oncology, a barrier that START has addressed by targeting community treatment centers, where 90 percent of cancer care occurs. These samples will also be available for further research in areas of RNA and protein analysis to complement the DNA sequencing.


'/>"/>

Contact: Jia Liu
liujia@genomics.cn
BGI Shenzhen
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. University of Minnesota startup offers game-changing energy solutions that reduce CO2 emissions
2. Starting a family does not encourage parents to eat healthier
3. Lets get moving: Unraveling how locomotion starts
4. Scientists start explaining Fat Bastards vicious cycle
5. NTU start-up launches worlds first 3-in-1 water monitoring system
6. Work starts on fossil fuel free cargo ship set to transform shipping industry
7. Large, medically important class of proteins starts to yield its secrets
8. New research association started: Magnesium implants shall facilitate bone fracture healing
9. To know a tiger is at least to start tolerating them, study shows
10. ERC starting grant for Friederike Range
11. Academia should fulfill social contract by supporting bioscience startups, case study says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... In today,s world, we simply cannot do without lasers. We ... weld, cut, or bend car components, survey roads, monitor our ... from the Fraunhofer Institute for Applied Solid State Physics IAF ... Their quantum cascade laser a particular type of infrared ...
... 2013 -- Research!America,s 18th annual Advocacy Awards will honor ... distinguished in their commitment to advancing medicine and health. ... 2014, at the Andrew W. Mellon Auditorium in Washington, ... The 2014 Advocacy Award winners are actress Glenn ...
... Bizkaia, Bilbao Chemicals (Barakaldo 1947-1987) and Nexana (Erandio 1952-1982), ... environment with no control whatsoever. Today we have become ... by this dumping and the difficulty in achieving this ... destroy the lindane mixed with the soil. A study ...
Cached Biology News:Lasers offer an automated way to test drinking water 2Lasers offer an automated way to test drinking water 3Research!America honors leaders in medical and health research advocacy 2Research!America honors leaders in medical and health research advocacy 3Research!America honors leaders in medical and health research advocacy 4A fresh solution for the lindane problem 2A fresh solution for the lindane problem 3
(Date:6/3/2015)... Charlotte, NC (PRWEB) June 03, 2015 ... announce the issuance of US Patent No. 9,044,273, ... on improving the thoraco-lumbar spinal fusion implant procedure ... replacing them with one easy-to-use disposable instrument tray. ... provide for numerous benefits over previous technology. Intelligent ...
(Date:6/2/2015)... , June 2, 2015 TapImmune, Inc. ... its institutional investors have reached an agreement whereby the ... short term warrants to provide the Company up to ... an effective S-1 registration statement. Under the restructured terms ... also call additional warrants which could result in a ...
(Date:6/2/2015)... TORONTO , June 2, 2015 /PRNewswire/ - Aptose Biosciences ... company developing new therapeutics that target the underlying mechanisms ... Drug Administration (FDA) has granted the company orphan drug ... leukemia (AML). APTO-253, a first-in-class inducer of the KLF4 ... Phase Ib clinical trial in patients with AML, high-risk ...
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6wjpd6/bioburden_testing ) has announced the ... , Test, Application & End User - Forecast to ... bioburden testing market is expected to reach $565.6 Million ... a CAGR of 9.8% from 2014 to 2019 ... market is segmented into consumables and instruments. The consumables ...
Breaking Biology Technology:Intelligent Implant Systems Announces US Patent Attained for Revolution™ Spinal System 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Bioburden Testing Market 2015 - Global Forecasts to 2019 2
... , ... ... ... ...
... ... with a Complete, Cloud-Enabled API for Developers , ... Westborough, Mass. (Vocus) March 4, 2010 -- This seminar details the fast-growing ... The free seminar will include lunch, discussion, and startup to Free Basic Account. , ...
... ... ... ... ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009 2OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009 3GenomeQuest Hosting Seminar at X Gen Congress In San Diego 2GenomeQuest Hosting Seminar at X Gen Congress In San Diego 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 28Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 29Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 30Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 31Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 32
Rabbit Polyclonal antibody to Perilipin Applications: This antibody is useful for Western blot anlaysis where a band at ~60 kDa is seen....
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
... Mch3 Lyophilized solid. Highly active ... kinetics, cleavage of target substrates, and inhibitor screening. ... One unit is defined as the amount of enzyme ... 235400 per hour at 37 C at saturated substrate ...
HLA-DRbeta (DA2)...
Biology Products: